Heartflow, Inc.
HTFL- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001464521
In the last 90 days, Heartflow, Inc. insiders filed 0 open-market purchases and 13 sales; 193 institutions reported holding it in 13F filings for Q2 2026, worth $2.19B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Heartflow, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 13 filings
- 3 insiders, $13.1M in total
- Insiders trading
- 3
- Net value
- −$13.1M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Heartflow, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Rogers Campbell | Chief Medical Officer | 79,956 | Sep 21, 2026 | 12 |
| Verghese Vikram | Chief Financial Officer | 155,183 | Sep 18, 2026 | 10 |
| Farquhar John C.M. | Chief Executive Officer | 321,914 | Sep 14, 2026 | 17 |
| Jones Marie L. | Chief Accounting Officer | 32,176 | Aug 10, 2026 | 4 |
| Lightcap Jeffrey C | Director | 293,681 | Jul 28, 2026 | 4 |
| Barabe Timothy C | Director | 188,231 | Jul 24, 2026 | 5 |
| Weldon William C | Director | 243,931 | Jul 10, 2026 | 2 |
| Riley Wayne Joseph | Director | – | Jun 18, 2026 | 1 |
| Tansey Casey M | Director | 16,447 | Jun 18, 2026 | 1 |
| Cullivan Julie A | Director | 27,291 | Jun 18, 2026 | 3 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 8,448,158Indirect | Apr 30, 2026 | 2 |
| Bain Capital Life Sciences Fund III, L.P. | 10% Owner | 8,448,158Indirect | Apr 30, 2026 | 2 |
| BCLS Fund III Investments GP, LLC | 10% Owner | 8,448,158Indirect | Apr 30, 2026 | 2 |
| Bain Capital Life Sciences III General Partner, LLC | 10% Owner | 8,448,158Indirect | Apr 30, 2026 | 2 |
| BCLS Fund III Investments, LP | 10% Owner | 8,448,158Indirect | Apr 30, 2026 | 2 |
| HealthCor Partners Management LP | Director | 0Indirect | Mar 26, 2026 | 1 |
| HealthCor Partners Fund LP | 10% Owner | 4,615,542Indirect | Aug 22, 2025 | 0 |
| HealthCor Partners LP | 10% Owner | 4,615,542Indirect | Aug 22, 2025 | 0 |
| HealthCor Partners GP, LLC | 10% Owner | 4,615,542Indirect | Aug 22, 2025 | 0 |
| HealthCor Partners Fund II, L.P. | 10% Owner | 4,615,542Indirect | Aug 22, 2025 | 0 |
| HealthCor Partners II, L.P. | 10% Owner | 4,615,542Indirect | Aug 22, 2025 | 0 |
| Hcpciv 1, LLC | 10% Owner | 4,615,542Indirect | Aug 22, 2025 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 (view filing)6:19 PM ET | Sep 18 | 3 days | Rogers CampbellChief Medical Officer | SSale | −19.7K | $50.15 | −$987.1K | −19.8%80.0K after | 10b5-1 |
| Sep 18, 2026 (view filing)8:46 PM ET | Sep 17-18 | 1 day | Verghese VikramChief Financial Officer | SSaleCommon Stock. | −24.3K | $50.55 | −$1.23M | −13.6%155.2K after | 2 lots10b5-1 |
| Sep 15, 2026 (view filing)7:44 PM ET | Sep 11-15 | 4 days | Verghese VikramChief Financial Officer | SSaleCommon Stock. | −35.0K | $50.08 | −$1.75M | −16.3%179.5K after | 3 lots10b5-1 |
| Sep 14, 2026 (view filing)6:41 PM ET | Sep 10-11 | 4 days | Farquhar John C.M.Chief Executive Officer | SSale | −38.9K | $46.78 | −$1.82M | −10.8%321.9K after | 2 lots10b5-1 |
| Sep 10, 2026 (view filing)5:24 PM ET | Sep 8 | 2 days | Verghese VikramChief Financial Officer | SSaleCommon Stock. | −6.64K | $50.03 | −$332.2K | −3.0%214.5K after | 10b5-1 |
| Sep 4, 2026 (view filing)5:29 PM ET | Sep 2-3 | 2 days | Verghese VikramChief Financial Officer | SSaleCommon Stock. | −33.4K | $49.85 | −$1.67M | −13.1%221.1K after | 2 lots10b5-1 |
| Aug 25, 2026 (view filing)5:32 PM ET | Aug 21 | 4 days | Farquhar John C.M.Chief Executive Officer | SSale | −27.2K | $50.00 | −$1.36M | −7.0%360.8K after | 10b5-1 |
| Aug 20, 2026 (view filing)5:56 PM ET | Aug 18 | 2 days | Farquhar John C.M.Chief Executive Officer | SSale | −32.7K | $45.00 | −$1.47M | −7.8%388.0K after | 10b5-1 |
| Aug 19, 2026 (view filing)9:04 PM ET | Aug 17 | 2 days | Rogers CampbellChief Medical Officer | SSale | −9.22K | $41.23 | −$380.1K | −9.6%86.5K after | 10b5-1 |
| Aug 18, 2026 (view filing)6:38 PM ET | Aug 14 | 4 days | Farquhar John C.M.Chief Executive Officer | SSale | −15.6K | $39.06 | −$607.8K | −3.6%420.7K after | 10b5-1 |
| Aug 12, 2026 (view filing)5:07 PM ET | Aug 10 | 2 days | Farquhar John C.M.Chief Executive Officer | SSale | −22.6K | $28.31 | −$638.7K | −4.9%436.3K after | 10b5-1 |
| Jul 17, 2026 (view filing)5:54 PM ET | Jul 15 | 2 days | Rogers CampbellChief Medical Officer | SSale | −9.22K | $25.72 | −$237.1K | −9.4%88.7K after | 10b5-1 |
| Jul 13, 2026 (view filing)8:25 PM ET | Jul 10 | 3 days | Farquhar John C.M.Chief Executive Officer | SSale | −22.6K | $27.75 | −$626.1K | −4.9%435.4K after | 10b5-1 |
| Jun 26, 2026 (view filing) | Jun 24 | 2 days | Farquhar John C.M.Chief Executive Officer | SSale | −38.9K | $35.00 | −$1.36M | −7.8%457.9K after | 10b5-1 |
| Jun 12, 2026 (view filing) | Jun 10 | 2 days | Farquhar John C.M.Chief Executive Officer | SSale | −22.6K | $28.50 | −$643.0K | −4.3%496.8K after | 10b5-1 |
| May 20, 2026 (view filing) | May 18 | 2 days | Rogers CampbellChief Medical Officer | SSale | −9.22K | $28.34 | −$261.3K | −10.5%78.7K after | 10b5-1 |
| May 13, 2026 (view filing) | May 11 | 2 days | Farquhar John C.M.Chief Executive Officer | SSale | −22.6K | $29.12 | −$657.0K | −4.2%519.4K after | 10b5-1 |
| Apr 30, 2026 (view filing)8:46 PM ET | Apr 28-30 | 2 days | Bain Capital Life Sciences Investors, LLC and 4 others10% Owner | SSale | −2.00M | $29.45 | −$58.9M | −19.1%8.45M after | 4 lots |
| Apr 14, 2026 (view filing) | Apr 10 | 4 days | Farquhar John C.M.Chief Executive Officer | SSale | −22.6K | $26.72 | −$602.9K | −3.9%549.2K after | 10b5-1 |
| Apr 3, 2026 (view filing) | Apr 1 | 2 days | Rogers CampbellChief Medical Officer | SSale | −64.5K | $24.64 | −$1.59M | −44.3%81.0K after | 10b5-1 |
| Mar 23, 2026 (view filing) | Mar 19 | 4 days | Rogers CampbellChief Medical Officer | SSale | −64.5K | $25.69 | −$1.66M | −45.1%78.5K after | 10b5-1 |
| Mar 20, 2026 (view filing) | Mar 18 | 2 days | Farquhar John C.M.Chief Executive Officer | SSale | −9.72K | $25.00 | −$243.1K | −1.7%571.7K after | 10b5-1 |
| Mar 12, 2026 (view filing) | Mar 10 | 2 days | Farquhar John C.M.Chief Executive Officer | SSale | −12.8K | $22.66 | −$290.9K | −2.2%581.5K after | 10b5-1 |
| Mar 6, 2026 (view filing) | Mar 5 | 1 day | Cullivan Julie ADirector | SSale | −9.12K | $25.00 | −$228.1K | −25.1%27.3K after | 10b5-1 |
| Feb 17, 2026 (view filing) | Feb 12 | 5 days | Rogers CampbellChief Medical Officer | SSale | −65.2K | $24.49 | −$1.60M | −46.1%76.0K after | 10b5-1 |
| Feb 10, 2026 (view filing) | Feb 10 | Same day | Farquhar John C.M.Chief Executive Officer | SSale | −22.6K | $27.46 | −$619.6K | −3.7%591.7K after | 10b5-1 |
| Feb 6, 2026 (view filing)4:58 PM ET | Feb 4 | 2 days | Bain Capital Life Sciences Investors, LLC and 4 others10% Owner | SSale | −2.00M | $28.05 | −$56.1M | −16.1%10.4M after | |
| Feb 6, 2026 (view filing) | Feb 5 | 1 day | Cullivan Julie ADirector | SSale | −8.00K | $27.32 | −$218.6K | −18.0%36.4K after | 10b5-1 |
| Dec 17, 2025 (view filing) | Dec 16 | 1 day | Lightcap Jeffrey CDirector | PPurchase | +40.0K | $26.34 | +$1.05M | New position40.0K after |